MSD and AstraZeneca’s Lynparza will be the first PARP inhibitor to be reviewed in Europe for the treatment of breast cancer, after the European Medicines Agency validated the drug’s marketing application in this setting.
Following a meeting of the executive steering group earlier this month, PharmaTimes Media has been busily contacting each and every entrant to the highly prestigious Clinical Researcher of the Year – The Americas competition to reveal their fate.
PharmaTimes Communications Team of the Year has a long history of being the only pharma industry award that tests the competencies and potential of communications agency teams, benchmarking talent agency side. Such is the popularity of the competition that the decision has been taken to increase the number of categories and with it, the opportunity for agencies – and individuals - to shine.
Some patients receiving chemotherapy after surgery for bowel cancer might only need three months of treatment rather than the six months currently given, according to new research published in Lancet Oncology.